Development and External Validation of a Nomogram for Predicting the Effect of RTX on the Treatment of Membranous Nephropathy

References

• du Buf-Vereijken P, Branten A, Wetzels J. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46(6):1012–1029. doi:10.1053/j.ajkd.2005.08.020
   PubMed Web of Science ®Google Scholar
• Francis J, Beck L, Salant D. Membranous nephropathy: a journey from bench to bedside. Am J Kidney Dis. 2016;68(1):138–147. doi:10.1053/j.ajkd.2016.01.030
   PubMed Web of Science ®Google Scholar
• Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. doi:10.1038/s41572-021-00303-z
   PubMed Web of Science ®Google Scholar
• Tomas N, Beck L, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287. doi:10.1056/NEJMoa1409354
   PubMed Web of Science ®Google Scholar
• Reinhard L, Machalitza M, Wiech T, et al. Netrin G1 is a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol. 2022;33(10):1823–1831. doi:10.1681/ASN.2022050608
   PubMed Web of Science ®Google Scholar
• Hoxha E, Reinhard L, Stahl R. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466–478. doi:10.1038/s41581-022-00564-1
   PubMed Web of Science ®Google Scholar
• Sethi S. New “Antigens” in membranous nephropathy. J Am Soc Nephrol. 2021;32(2):268–278. doi:10.1681/ASN.2020071082
   PubMed Web of Science ®Google Scholar
• van de Logt A, Fresquet M, Wetzels J, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292–1302. doi:10.1016/j.kint.2019.07.014
   PubMed Web of Science ®Google Scholar
• Burbelo P, Joshi M, Chaturvedi A, et al. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol. 2020;31(1):208–217. doi:10.1681/ASN.2019050538
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi:10.1016/j.kint.2021.05.021
   PubMedGoogle Scholar
• Pescovitz M. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5):859–866. doi:10.1111/j.1600-6143.2006.01288.x
   PubMed Web of Science ®Google Scholar
• van de Logt A, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016–1017. doi:10.1016/j.kint.2017.12.019
   PubMed Web of Science ®Google Scholar
• Rovin B, Adler S, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779. doi:10.1016/j.kint.2021.05.015
   PubMed Web of Science ®Google Scholar
• Fervenza F, Appel G, Barbour S, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46. doi:10.1056/NEJMoa1814427
   PubMed Web of Science ®Google Scholar
• Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972–982. doi:10.1681/ASN.2020071091
   PubMed Web of Science ®Google Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348–358. doi:10.1681/ASN.2016040449
   PubMed Web of Science ®Google Scholar
• Peponis V, Kyttaris V, Chalkiadakis S, Bonovas S, Sitaras N. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus. 2010;19(6):675–682. doi:10.1177/0961203309360539
   PubMed Web of Science ®Google Scholar
• Perna A, Ruggiero B, Podestà M, et al. Sexual dimorphic response to rituximab treatment: a longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome. Front Pharmacol. 2022;13:958136. doi:10.3389/fphar.2022.958136
   PubMed Web of Science ®Google Scholar
• Kim D, Lee A, Jung Y, et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway. Nephrol Dial Transplant. 2014;29(11):2043–2053. doi:10.1093/ndt/gfu240
   PubMed Web of Science ®Google Scholar
• Kim S, Lee K, Kim J, Choi H. Estrogenic compound attenuates angiotensin II-induced vascular smooth muscle cell proliferation through interaction between LKB1 and estrogen receptor α. J Pharmacol Sci. 2016;132(1):78–85. doi:10.1016/j.jphs.2016.09.001
   PubMed Web of Science ®Google Scholar
• Li Y, Ding X, Li H, Zhang Y, Bao J. Role of G protein-coupled estrogen receptor 1 in modulating transforming growth factor-β stimulated mesangial cell extracellular matrix synthesis and migration. Mol Cell Endocrinol. 2014;391(1–2):50–59. doi:10.1016/j.mce.2014.04.014
   PubMed Web of Science ®Google Scholar
• Doublier S, Lupia E, Catanuto P, et al. Testosterone and 17β-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int. 2011;79(4):404–413. doi:10.1038/ki.2010.398
   PubMed Web of Science ®Google Scholar
• Matrai M, Hetthéssy J, Nadasy G, et al. Estrogen therapy may counterbalance eutrophic remodeling of coronary arteries and increase bradykinin relaxation in a rat model of menopausal hypertension. Menopause. 2016;23(7):778–783. doi:10.1097/GME.0000000000000654
   PubMed Web of Science ®Google Scholar
• Teisseyre M, Cremoni M, Boyer-Suavet S, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy. Front Immunol. 2022;13:859419. doi:10.3389/fimmu.2022.859419
   PubMed Web of Science ®Google Scholar
• Seitz-Polski B, Dahan K, Debiec H, et al. High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol. 2019;14(8):1173–1182. doi:10.2215/CJN.11791018
   PubMed Web of Science ®Google Scholar
• Boyer-Suavet S, Andreani M, Cremoni M, et al. Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. 2019;34(8):1423–1425. doi:10.1093/ndt/gfz041
   PubMed Web of Science ®Google Scholar
• Jacobs R, Langer-Jacobus T, Duong M, et al. Detection and quantification of rituximab in the human urine. J Immunol Methods. 2017;451:118–121. doi:10.1016/j.jim.2017.09.001
   PubMed Web of Science ®Google Scholar